Ge Healthcare As

Ge Healthcare Limited

Nycomed Imaging As

Amersham Health As

Other

Bayer Pharma Aktiengesellschaft

Hammersmith Imanet Limited

Bayer As

Imperial College

Alan Cuthbertson

Magne Solbakken

Jo Klaveness

Bard Indrevoll

Anne Naevestad

Harry John Wadsworth

Helge Tolleshaug

Hege Karlsen

Torgrim Engell

Anthony Eamon Storey

P&aring;l Rongved

Alexander Mark Gibson

Lars Hoff

Halldis Hellebust

Colin Mill Archer

Anders H&oslash;gset

Joseph Maduabuchi Arukwe

Bente E Arbo

Peter Kremminger

Franz Rovenszky

Michael Hartmann

Matthias Eberhard Glaser

Henry Raphael Wolfe

Johann Hiebl

Duncan George Wynn

Marivi Mendizabal

Peter Fischer

Mette Husbyn

Hermann Kollmann

Jessie Sandosham

Anne N&aelig;vestad

Dagfinn L&oslash;vhaug

Bård Indrevoll

Klaus Bryn

Morten Eriksen

Erik Arstad

Aslak Godal

Sajinder Kaur Luthra

Frank Brady

Nigel Anthony Powell

Robert James Nairne

Eric Ofori Aboagye

Edvin Wilhelm Johannesen

Lars Linden

Ian Andrew Wilson

Olav B Ryan

Dagfinn Lovhaug

Philip Duncanson

Dag Erlend Olberg

Lisa Iddon

Klaus Kopka

Janne Olsen Frenvik

Nicholas Toby Jeffery

Bodo Levkau

Maria E Verdugo-Gazdik

Julie Davis

Sally-Ann Ricketts

Kirsty Heywood

Michael Schafers

Stefan Wagner

Hans-Jörg Breyholz

Mark Dixon

Edward R Bacon

Vinay Chandrakant Desai

Sajinker Kaur Luthra

Sudhakar Kasina

Julius Leyton

Geir Gogstad

The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.

Radio-pharmaceutical complexes

Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).

Radiolabelled octreotate analogues as PET tracers

The invention relates to contrast agents for detection of the Urokinase Plasminogen Activator Receptor (uPAR). More specifically the invention relates to contrast agents comprising a peptidic vector binding to the uPAR, labelled with an imageable moiety.

uPAR-targeting contrast agents

The Invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

Diagnostic compounds

The present invention relates to labelled cMet binding peptides suitable for optical imaging in vivo. The peptides are labelled with an optical reporter group suitable for imaging in the red to near-infrared region. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods, especially of use in the detection, staging, diagnosis, monitoring of disease progression or monitoring of treatment of colorectal cancer (CRC).

Peptide imaging agents

The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

Radiofluorination methods

The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.

Peptide-based compounds

The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.

The present invention provides novel compounds and pharmaceutical compositions containing such compounds, wherein the compounds have affinity for proteoglycans. The compounds comprise an amino acid based core unit linked to positively charged moieties. The compounds further comprise at least one imaging moiety detectable in in vivo imaging making the compounds useful as diagnostic contrast agents for imaging of proteoglycans, such as heparan sulphate proteoglycans.

Contrast agents

This invention relates to new peptide-based compounds and their use in therapeutically effective treatments as well as for diagnostic imaging techniques. More specifically the invention relates to the use of such peptide-based compounds used as targeting vectors that bind to receptors associated with angiogenesis, in particular the &#x3b1;v&#x3b2;3 integrin receptor. Such contrast agents may thus be used for diagnosis of for example malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. Moreover such compounds may also be used in therapeutic treatment of these diseases.

This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD.

Optical imaging

The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

Diagnostic imaging agents with MMP inhibitory activity

The invention relates to novel processes for the purification of radiolabelled tracers, using a solid-support bound scavenger group. The general concept being illustrated by the scheme:

Purification methods

Growing community of inventors

Oslo, Norway

Alan Cuthbertson